98%
921
2 minutes
20
Pulmonary embolism (PE) is classified into massive, submassive, and low-risk categories, with severity often assessed using tools such as the Pulmonary Embolism Severity Index (PESI) and simplified PESI (sPESI) to determine inpatient versus outpatient management. This report discusses an 84-year-old male with a history of prostate cancer (not on chemotherapy), hypertension, type 2 diabetes mellitus, and hyperlipidemia, who developed bilateral PE and a right heart thrombus in transit after a syncopal episode during hospitalization for a viral illness. A right heart thrombus in transit is a mobile clot within the right heart chambers or vena cava, posing a high risk for further embolization. These thrombi are often visualized on echocardiography and are considered a medical emergency. Although the patient remained hemodynamically stable, evidence of right ventricular dysfunction confirmed by laboratory markers (e.g., elevated troponin and BNP levels) and imaging studies was consistent with the diagnosis of submassive PE. Management of right heart thrombi in transit remains controversial due to the lack of randomized controlled trials. Treatment options include systemic anticoagulation, systemic or catheter-directed thrombolysis, catheter-based embolectomy, and surgical thrombectomy. In elderly patients with multiple comorbidities, selecting the optimal approach requires multidisciplinary input. This case highlights the critical need for multidisciplinary evaluation and the complexity of managing right heart thrombi and the importance of individualized treatment strategies in high-risk patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12111494 | PMC |
http://dx.doi.org/10.7759/cureus.84909 | DOI Listing |
J Thromb Haemost
September 2025
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
Background: Balancing the risks of thrombotic and bleeding events in people with advanced kidney disease is a clinical challenge.
Objectives: To estimate rates of major adverse thrombotic events (MATEs) and bleeding events in individuals with chronic kidney disease (CKD) stages 4 or 5 or with end-stage kidney disease (ESKD) receiving hemodialysis (HD) or peritoneal dialysis (PD).
Methods: Using administrative claims from a 20% Medicare sample, Optum's de-identified Clinformatics Data Mart Database, and the US Renal Data System from 2016-2019, we identified individuals with CKD stages 4 or 5 and individuals with dialysis-dependent ESKD.
Am J Respir Crit Care Med
September 2025
Hôpital Avicenne, Medical-Surgical Intensive Care Unit, Bobigny, Île-de-France, France;
Emerg Radiol
September 2025
Monash Imaging, Monash Health, VIC, Clayton, Australia.
Purpose: To evaluate the efficacy and complications of absorbable haemostatic gelatin uterine artery embolisation for symptomatic acquired uterine arterio-venous malformation (UAVM).
Methods: All the adult female patients who had acute urogenital bleeding due to UAVM confirmed on ultrasound and received uterine artery embolisation (UAE) for UAVM in a tertiary institution between January 2000 and October 2024 were included. Patients who had UAE for other causes were excluded.
Eur J Case Rep Intern Med
August 2025
Internal Medicine, University of California, Riverside School of Medicine, Riverside, USA.
Introduction: Pulmonary embolism (PE) is a life-threatening condition with well-defined management strategies; however, the presence of a clot-in-transit (CIT)-a mobile thrombus within the right heart-introduces a uniquely high-risk scenario associated with a significantly elevated mortality rate. While several therapeutic approaches are available-including anticoagulation, systemic thrombolysis, surgical embolectomy, and catheter-directed therapies-there is no established consensus on a superior treatment modality. Catheter-based mechanical thrombectomy has emerged as a promising, minimally invasive alternative that mitigates the bleeding risks of systemic thrombolysis and the invasiveness of surgery.
View Article and Find Full Text PDFCureus
August 2025
Respiratory Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Tuberculosis (TB) is a multisystem infectious disease with both pulmonary and extrapulmonary manifestations. TB can also induce a hypercoagulable state, setting off a cascade of changes in the body, including systemic inflammation, endothelial dysfunction, and abnormalities in the coagulation and fibrinolytic pathways. Collectively, these factors significantly increase the risk of venous thromboembolism, such as deep vein thrombosis and pulmonary embolism.
View Article and Find Full Text PDF